<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072016</url>
  </required_header>
  <id_info>
    <org_study_id>4046</org_study_id>
    <nct_id>NCT04072016</nct_id>
  </id_info>
  <brief_title>Study of the Beacon Aqueous Microshunt in Patients With Refractroy Glaucoma</brief_title>
  <acronym>Beacon</acronym>
  <official_title>The Beacon Study: A Prospective, Multicenter Study to Evaluate the Safety and Effectiveness of Beacon Aqueous Microshunt for Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroOptx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroOptx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, single-arm clinical study to evaluate the safety and
      effectiveness of Beacon Aqueous Microshunt in patients with refractory glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>12 Months</time_frame>
    <description>20% mean diurnal IOP reduction from baseline, on the same number or fewer topical IOP-lowering medications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 Months</time_frame>
    <description>Rate of occurrence of serious procedure-related and/or device-related adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate defined as achieving at least 20% mean diurnal IOP reduction from baseline</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from baseline in IOP</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer tear test - mean change from baseline</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Beacon Aqueous Microshunt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Beacon Aqueous Microshunt</intervention_name>
    <description>The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.</description>
    <arm_group_label>Beacon Aqueous Microshunt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Refractory glaucoma: Prior failure of filtering/cilioablative procedure and/or
             uncontrolled IOP on maximum-tolerated medication (i.e. &gt;=4 classes of topical lowering
             medications, or fewer in the case of tolerability or efficacy issues).

          2. Primary open-angle, traumatic or neovascular glaucoma.

          3. Medicated DIOP ≥20 mmHg and ≤45 mmHg on maximum-tolerated medical therapy.

          4. Best-corrected baseline visual acuity of light perception or better in study eye.

          5. Participant has the understanding, ability, and willingness to fully comply with study
             procedures and postoperative care instructions.

          6. Participant understands and signs the informed consent.

        Exclusion Criteria:

          1. No light perception vision.

          2. Pigmentary glaucoma in study eye.

          3. Pseudoexfoliation syndrome in study eye.

          4. Need for glaucoma surgery combined with other ocular procedures in the study eye at
             the time of implant (e.g. cataract surgery, penetrating keratoplasty, or retinal
             surgery).

          5. Unwilling to discontinue contact lens use in the study eye after surgery.

          6. Any condition that prevents the device implantation in the superior region of the
             study eye.

          7. Life expectancy &lt;1 year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roy Martin</last_name>
    <phone>763-670-5600</phone>
    <email>rmartin@microoptx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icon Eye Care</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Bosch</last_name>
      <phone>970-205-9555</phone>
    </contact>
    <investigator>
      <last_name>James Fox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Baker</last_name>
      <phone>952-567-6198</phone>
    </contact>
    <investigator>
      <last_name>Patrick J Riedel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iWorks Laser and Vision Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Jenkins</last_name>
      <phone>937-226-7870</phone>
    </contact>
    <investigator>
      <last_name>Patrick L Spencer, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

